- Home
- LE vs TVRD Comparison
LE vs TVRD Comparison
Compare LE & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- TVRD
- Stock Information
- Founded
- LE 1963
- TVRD 2017
- Country
- LE United States
- TVRD United States
- Employees
- LE N/A
- TVRD N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- LE Consumer Discretionary
- TVRD Health Care
- Exchange
- LE Nasdaq
- TVRD Nasdaq
- Market Cap
- LE 280.4M
- TVRD 246.5M
- IPO Year
- LE N/A
- TVRD N/A
- Fundamental
- Price
- LE $9.32
- TVRD $25.77
- Analyst Decision
- LE Strong Buy
- TVRD Strong Buy
- Analyst Count
- LE 1
- TVRD 3
- Target Price
- LE $20.00
- TVRD $60.67
- AVG Volume (30 Days)
- LE 633.2K
- TVRD 56.7K
- Earning Date
- LE 06-05-2025
- TVRD 05-13-2025
- Dividend Yield
- LE N/A
- TVRD N/A
- EPS Growth
- LE N/A
- TVRD N/A
- EPS
- LE 0.14
- TVRD N/A
- Revenue
- LE $1,338,672,000.00
- TVRD N/A
- Revenue This Year
- LE $3.31
- TVRD N/A
- Revenue Next Year
- LE $2.34
- TVRD N/A
- P/E Ratio
- LE $67.51
- TVRD N/A
- Revenue Growth
- LE N/A
- TVRD N/A
- 52 Week Low
- LE $7.65
- TVRD $8.13
- 52 Week High
- LE $19.88
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- LE 54.05
- TVRD N/A
- Support Level
- LE $8.50
- TVRD N/A
- Resistance Level
- LE $9.76
- TVRD N/A
- Average True Range (ATR)
- LE 0.83
- TVRD 0.00
- MACD
- LE 0.08
- TVRD 0.00
- Stochastic Oscillator
- LE 79.15
- TVRD 0.00
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.